Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Efficacy in Preclinical Studies

Tonix Pharmaceuticals has showcased promising preclinical results for its single-dose mpox vaccine candidate TNX-801 at the World Vaccine Congress Washington 2025, highlighting significant potential for addressing global health emergencies related to mpox outbreaks.

The oral presentation revealed that TNX-801, a minimally replicative live-virus vaccine, demonstrated exceptional efficacy in protecting animal subjects against mpox and rabbitpox. Notably, the vaccine provided comprehensive protection across different immunological profiles, including immunocompromised subjects, with sustained immunity lasting up to six months.

The vaccine's design aligns closely with the World Health Organization's preferred target profile for mpox vaccines, suggesting potential broad applicability in current and future outbreak scenarios. This characteristic is particularly critical given the recent global health emergencies involving mpox, which have underscored the need for effective preventative measures.

By developing a single-dose vaccine with durable protection, Tonix Pharmaceuticals addresses key challenges in mpox prevention. The approach could significantly simplify vaccination protocols, potentially increasing accessibility and reducing logistical complexities associated with multi-dose immunization strategies.

The preclinical data represent a significant milestone in mpox vaccine development, offering hope for more effective public health interventions against this infectious disease. As global health authorities continue to monitor mpox transmission, innovations like TNX-801 could play a crucial role in mitigating future outbreak risks.